Docon Technologies Sells 10% Stake in Thyrocare for ₹667.69 Crore, Promoter Holding Drops to 60.93%

Mumbai, 24 October 2025: Docon Technologies Private Limited has divested 53,32,860 equity shares, representing 10% of Thyrocare Technologies Limited’s (NSE: THYROCARE, BSE: 539871) paid-up capital, through open market transactions today. The total consideration from the sale stands at ₹667.69 crore, with shares sold at an average price of ₹1,252.03 per share, reflecting strong valuation for the leading diagnostics firm.

Headquartered in Navi Mumbai, Thyrocare Technologies Limited is a prominent diagnostic and preventive healthcare service provider. Operating automated laboratories nationwide, the company offers an extensive range of pathology and wellness tests. Listed on both the NSE and BSE, Thyrocare is recognised for its low-cost, high-efficiency model, serving both retail and institutional clients and maintaining consistent operational performance amid market shifts.

Promoter Stake Falls to 60.93% After ₹667.69 Crore Sale by Docon Technologies

Docon Technologies remains a promoter but has reduced its holding from 70.98% to 60.93%, marking a 10.05% drop in promoter ownership. This strategic stake sale provides substantial liquidity while retaining majority control. The move aligns with trends of partial promoter exits in India’s healthcare diagnostics sector, allowing capital reallocation without disrupting operations or market confidence.

Thyrocare Shares Rise 1.58% to ₹1,271.70, Trading Peaks at ₹1,279 Amid Stake Sale

Following the transaction, Thyrocare’s share price showed a moderate uptick of 1.58% to ₹1,271.70 by 1:03 PM IST, up from the opening price of ₹1,262. The intraday high reached ₹1,279, while the low was ₹1,252, reflecting steady market absorption of the stake sale news. Trading volumes remained robust with 71.29 lakh shares exchanged, translating to a traded value of ₹894.22 crore, and the company’s market capitalization stood at ₹6,726.59 crore, with a free-float market cap of ₹1,939.11 crore.

The share price reaction demonstrates that the partial promoter exit was smoothly integrated into market dynamics, with steady buying interest keeping the stock above key intraday support levels.

Thyrocare Stock Gains Over 50% in Six Months on Diagnostics Sector Momentum

Thyrocare Technologies has delivered strong market performance, with key gains over different periods:

• 1 Week: +₹25.40 (2.04%)
• 1 Month: +₹64.15 (5.32%)
• 6 Months: +₹423.55 (50.06%)
• 1 Year: +₹354.75 (38.78%)
• 2 Years: +₹731.10 (135.77%)

The stock’s six-month surge underscores growing optimism in the diagnostics segment, driven by the company’s cost-efficient automated laboratory network and expanding preventive healthcare demand across India.

The stake sale by Docon Technologies demonstrates a promoter-led liquidity event while maintaining control. Thyrocare’s share price responded positively, rising to ₹1,271.70 by 1:03 PM IST with sustained trading volumes, highlighting the market’s steady absorption of the transaction and the company’s continued operational stability.

REF: https://nsearchives.nseindia.com/corporate/THYROCARE_24102025114551_SE_Letter.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations